High glucose increases Aβ production by HEK293 APPsw cells while benfotiamine prevents this increase. This is correlated with the modulation of GSK-3 activity.
Introduction
Alzheimer's disease (AD) is characterized clinically by progressive cognitive impairment and pathologically by the presence of extracellular senile plaques and intracellular neurofibrillary tangles in the brain. Senile plaques are largely composed of β-amyloid 1-42 (Aβ 42 ), a 4-kD peptide derived from Aβ precursor protein (APP). Aβ 42 is toxic to neurons. The deposition of Aβ and the formation of senile plaques are considered to be the primary causes of AD. However, the exact process of pathogenesis remains to be clarified. Recent evidence from population-based studies has shown a link between diabetes mellitus (DM) and AD [1] [2] [3] [4] . DM significantly increases the risk for cognitive dysfunction, especially AD-type dementia [5] [6] [7] . Also, AD patients have a high risk of developing type II DM [8, 9] . Experimental investigations suggest that abnormal cerebral glucose metabolism is a key etiological factor [1, 24] .
Glycogen synthase kinase-3 (GSK-3), a serine/threonine protein kinase, is involved in regulating glucose metabolism and plays an important role in many physiological and pathological processes. Interestingly, recent studies have shown that GSK-3 contributes to AD pathogenesis [10] ,
and inhibiting GSK-3 activity reduces cerebral Aβ produc-tion and accumulation in APP-overexpressing mice [11] . In a previous study, we demonstrated the beneficial effect of benfotiamine against Aβ production in an APP/presenilin-1 (APP/PS1) double transgenic mouse model [12] , and this was correlated with the inhibition of GSK-3 activity. Here, we used HEK293 cells with APP Swedish mutant (APPsw) overexpression to determine whether high glucose affects Aβ production and whether benfotiamine plays a role in its regulation. Furthermore, the possible mechanism by which high glucose and benfotiamine affect Aβ production was investigated. Then, the cells were switched to medium containing CCK-8
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at a final ratio of 10%. After 2-h incubation at 37°C, the absorbance at 450 nm was measured using a 96-well microplate spectrophotometer. 
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Statistical analysis
All data are shown as mean ± SEM. Student's t-test was used to evaluate statistical significance. All statistical analyses were performed using Origin 7.0 (OriginLab, Northampton, MA).
Results
Effects of glucose concentration on Aβ production
Different glucose concentrations had complex effects on Aβ production. .31 pg/mL, P >0.05; Fig. 1 ).
Effects of glucose on the viability of HEK293
APPsw cells The OD values under the glucose concentrations used showed no significant differences (0.74 ± 0.01 for phospho-GSK-3α/GSK-3α, P <0.01; 1 ± 0.001 for phospho-GSK-3β/GSK-3β, P <0.05, Fig. 2A, B) . Con- 
Discussion
Limiting Aβ production could become an important therapeutic target in AD [13] . Recent studies have shown that AD is associated with perturbed glucose metabolism [14, 15] .
Mild to moderate impairments of cognitive functions have been reported in patients with Type I [16] and Type II DM [17, 18] . DM appears to be a significant risk factor for AD in several epidemiological studies [4, 19] . The previous studies have reported that high glucose can increase Aβ deposition and tau phosphorylation in the experimental animal brain [1, 10] . Here, we demonstrated that different concentra- (Fig. 1) . This may be due to reduced viability of HEK293 APPsw cells caused by glucose >5.5 g/L [25] . Therefore, our study indicates that high glucose within a limited range of concentrations significantly enhances Aβ production in HEK293 APPsw cells.
Our previous study reported that benfotiamine significantly reduces the formation of amyloid plaques in APP/ PS1 mice [12] . Here, we further demonstrated the inhibitory effect of benfotiamine on Aβ production by HEK293
APPsw cells under high glucose (5.5 g/L). It has been well documented that AD is associated with abnormal glucose metabolism [21, 26] . Experimental and clinical studies have demonstrated the beneficial effect of benfotiamine in preventing diabetic neuropathy [27, 28] . Thus, our study has major implications for preventing the pathological progress of AD by antagonizing the mechanism of impaired glucose metabolism.
Mechanistically, GSK-3 was first identified as a kinase involved in modulating glycogen metabolism. GSK-3 is a ubiquitous serine/threonine protein kinase involved in multiple physiological and pathological processes [12] . Specifically, GSK-3 is a key contributor to the insulin signaling cascade and the molecular pathogenesis of diabetes [29, 30] .
Interestingly, GSK-3 also contributes to the pathogenesis of AD [10, 20] . It reduces Aβ production and accumulation in APP-overexpressing mice by inhibiting GSK-3 activity [11] .
Benfotiamine increases the phosphorylation of Akt, an upstream kinase of GSK-3, in counteracting glucose toxicity and ischemic diabetes [22, 23] , which suggests that benfotiamine may also regulate GSK-3 activity. Our previous study reported that benfotiamine significantly enhances the phosphorylation levels and reduces the enzymatic activity of both GSK-3α and GSK-3β in APP/PS1 mice, suggesting that a GSK-3-dependent pathway is involved in the beneficial effects of benfotiamine [12] . The current study further demonstrated that benfotiamine decreased the activity of GSK3 in vitro.
In conclusion, this study is the first to demonstrate that high glucose alters Aβ production in HEK293 APPsw cells. Our data indicated that the inhibitory effects of benfotiamine on Aβ production by HEK293 APPsw cells under high glucose (5.5 g/L) may be through decreasing the activity of GSK-3. Since GSK-3 is a key enzyme in glucose metabolism and involved in Aβ production, the modulation of GSK-3 activity by benfotiamine could be beneficial in AD therapy.
